Illustrative image.

Zortress

Name: Zortress
Brand: Novartis
Availability: InStock

Everolimus

Prescription required

$525.00

0.25MG · 3 × 60 tablets · 3 months supply

BrandBranded medicine· By Novartis

$175.00 per month

Strength

How long a supply?

1 month$175.00 a monthOne-off$175.00

3 months$175.00 a monthOne-off$525.00

6 months$175.00 a monthOne-off$1050.00

Supplied from Israel

Test mode: no payment is taken. View cart

Annual cost

$2100a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

0.25MG

0.50mg

0.75mg

FDA boxed warningMalignancies and serious infections; kidney graft thrombosis; nephrotoxicity; and mortality in heart transplantation

Malignancies and Serious Infections

Only physicians experienced in immunosuppressive therapy and management of transplant patients should prescribe everolimus tablets. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient

Increased susceptibility to infection and the possible development of malignancies, such as lymphoma and skin cancer, may result from immunosuppression

Kidney Graft Thrombosis

An increased risk of kidney arterial and venous thrombosis, resulting in graft loss, was reported, mostly within the first 30 days posttransplantation

Nephrotoxicity

Mortality in Heart Transplantation

Increased mortality, often associated with serious infections, within the first three months posttransplantation was observed in a clinical trial of

de novo heart transplant patients receiving immunosuppressive regimens with or without induction therapy. Use in heart transplantation is not recommended

Only physicians experienced in immunosuppressive therapy and management of transplant patients should use everolimus tablets

Increased susceptibility to infection and the possible development of malignancies may result from immunosuppression

Increased mortality in a heart transplant clinical trial. Use in heart transplantation is not recommended

Read this with the rest of the clinical information

About Zortress

Overview

Zortress contains everolimus, a prescription medicine that suppresses the immune system. It is used with other medicines to help prevent organ rejection in adults after a kidney transplant when the risk of an immune reaction is low to moderate, or after a liver transplant. It works by blocking a protein called mTOR, which reduces the activation and growth of immune cells involved in rejection.

What it treats

- Prevention of kidney transplant rejection in adults at low to moderate immunologic risk, alongside basiliximab, cyclosporine and corticosteroids. - Prevention of liver transplant rejection in adults, alongside tacrolimus and corticosteroids. Treatment begins no earlier than 30 days after transplantation.

Safety information

Side effects

Common side effects reported in kidney transplant patients include swelling of the hands or feet, constipation, high blood pressure, nausea, anemia, urinary tract infection and high blood fat levels. In liver transplant patients, common side effects include diarrhea, headache, swelling of the hands or feet, high blood pressure, nausea, fever, abdominal pain, low white blood cell counts and high cholesterol. Contact a doctor promptly about serious side effects, including angioedema (swelling beneath the skin), delayed wound healing, fluid buildup, lung inflammation, protein in the urine, reactivation of certain viral infections that can damage the kidneys, and serious disorders involving blood clots in small blood vessels that can affect blood cells and kidneys. The risk of angioedema is higher when everolimus is taken with an ACE inhibitor. Taking it with cyclosporine may increase the risk of these blood-clotting disorders. Everolimus can also cause diabetes after transplantation and high cholesterol or triglycerides. Blood and urine tests are needed to monitor for some of these problems. Low or absent sperm counts may occur, affecting male fertility. Everolimus may harm an unborn baby. Use effective contraception during treatment and for 8 weeks after the final dose if you can become pregnant. Avoid live vaccines during treatment.

FDA boxed warning

Malignancies and serious infections; kidney graft thrombosis; nephrotoxicity; and mortality in heart transplantation

Malignancies and Serious Infections

Increased susceptibility to infection and the possible development of malignancies, such as lymphoma and skin cancer, may result from immunosuppression

Kidney Graft Thrombosis

An increased risk of kidney arterial and venous thrombosis, resulting in graft loss, was reported, mostly within the first 30 days posttransplantation

Nephrotoxicity

Mortality in Heart Transplantation

Increased mortality, often associated with serious infections, within the first three months posttransplantation was observed in a clinical trial of

de novo heart transplant patients receiving immunosuppressive regimens with or without induction therapy. Use in heart transplantation is not recommended

Only physicians experienced in immunosuppressive therapy and management of transplant patients should use everolimus tablets

Increased susceptibility to infection and the possible development of malignancies may result from immunosuppression

Increased mortality in a heart transplant clinical trial. Use in heart transplantation is not recommended

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Seek immediate medical attention for swelling of the face, lips, tongue or throat. - Seek immediate medical attention for fever, which may signal an infection. - Seek immediate medical attention for new or worsening swelling from fluid buildup, or problems with wound healing.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

Do not take Zortress (everolimus) if you are allergic to everolimus, sirolimus or any component of the tablets. Conditions requiring caution and monitoring include: • Angioedema (swelling), with an increased risk when taken with ACE inhibitors. • Delayed wound healing or fluid accumulation. • Non-infectious lung inflammation. • High cholesterol or triglycerides, protein in the urine, and new diabetes after transplantation. • Reactivation of polyomavirus infections, including BK virus–associated kidney disease. • TMA, TTP and HUS, serious blood disorders whose risk may increase when everolimus is taken with cyclosporine. Everolimus may cause harm during pregnancy, based on animal data. Women who could become pregnant should use effective contraception during treatment and for 8 weeks after the final dose. Breastfeeding is not recommended. Everolimus may impair fertility, including causing low or absent sperm counts. Avoid live vaccines during treatment.

Interactions

Tell your doctor if you take cyclosporine, ketoconazole, erythromycin, verapamil or rifampin, as these medicines may affect everolimus levels in your blood. Also tell your doctor if you use cannabidiol (CBD). Your doctor may need to monitor your everolimus blood levels and consider reducing your prescribed dose when it is used with CBD.

Using Zortress

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label EVEROLIMUS TABLET [I3 PHARMACEUTICALS, LLC] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.